First dedicated leaflet modification solution to enable TAVR in patients at risk of coronary obstruction.

The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.

Though arterial thrombotic risk was higher with hormonal contraception use, the absolute excess risks were low.

Intensifying oral diuretic therapy was linked to worse prognosis, but not everybody is sold on its use an endpoint.

The FDA says user challenges and need for additional procedures drove recommendations to stop using the system immediately.

Guidance around complete revascularization and intracoronary imaging is strengthened, and Impella gets a recommendation.

The phase II data are promising for patients who are managed with watchful waiting before being offered an intervention.

Clinicians having unconscious pro-white bias led to low-value PAD care and greater risks for amputation in Black patients.

Hopes for a separate board responsible for certifying cardiologists were dashed Friday when leaders laying the groundwork for ...

For all news and slides from the THT 2025 meeting, check out our conference page and or tune in to the Heart Sounds podcast ...

The polygenic risk score appears to identify patients who may benefit most from LDL-lowering therapy, say researchers.

There’s no scientific evidence to support anecdotal claims—on social media or elsewhere—of a bump, Jonathan Drezner says.